GlaxoSmithKline is taking some heat at home over questions about global shortages of its and Merck’s hepatitis B vaccine that triggered rationing in the U.K., although GSK’s supplies to the much larger U.S. market seem to be unaffected.
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
A report examining the European venture landscape for health and biotech firms over the first half of 2017 has found that there is a continuing positive environment for venture funding and M&A in the sector.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.